Top

Published in:

01-05-2015 | Original Article

Demographic and comorbidity profile of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a real-life clinical setting: Are 5-alpha-reductase inhibitor consumers different?

Authors: Ferdinando Fusco, Davide Arcaniolo, Massimiliano Creta, Gaetano Piccinocchi, Giovanni Arpino, Matteo Laringe, Roberto Piccinocchi, Nicola Longo, Paolo Verze, Francesco Mangiapia, Vittorio Imperatore, Vincenzo Mirone

Published in: World Journal of Urology | Issue 5/2015

Abstract

Purpose

We aimed to describe, in a daily clinical practice setting, the demographic and comorbidity profile of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (BPH-LUTS), to compare the characteristics of patients receiving 5-alpha-reductase inhibitors (5-ARIs) with those not receiving them and to investigate predictors of 5-ARI prescription.

Methods

We performed a retrospective observational study using data retrieved from a general practitioners database. Male patients with diagnosis of BPH-LUTS were included. The following demographic and clinical data were available and extracted: age, comorbidities, BPH-LUTS medical therapy, drugs for comorbidities. A subgroup analysis was performed according to the use of 5-ARIs. Factors associated with 5-ARI prescription were assessed with uni- and multivariate analyses.

Results

A total of 7,103 patients were identified. Most patients (71.7 %) were aged ≥65 years. Hypertension was present in 64.9 % of patients; it was the most prevalent comorbidity followed by diabetes mellitus, hypercholesterolemia, coronary artery disease and other dyslipidemias. Overall, 38.22 % of patients were treated with 5-ARIs. Mean age of patients taking 5-ARIs was significantly higher. The prevalence of hypertension and the use of antihypertensive drugs were significantly higher among patients receiving 5-ARIs. Older age was an independent predictor of 5-ARI prescription.

Conclusions

In a daily clinical practice setting, patients with BPH-LUTS receiving 5-ARIs are significantly older and have significantly higher prevalence of hypertension if compared with patients with BPH-LUTS not receiving 5-ARIs. Older age is an independent predictor of 5-ARI prescription.

Verhamme KM, Dieleman JP, Bleumink GS, van der Lei J, Sturkenboom MC, Artibani W, Begaud B, Berges R, Borkowski A, Chappel CR, Costello A, Dobronski P, Farmer RD, Jiménez Cruz F, Jonas U, MacRae K, Pientka L, Rutten FF, van Schayck CP, Speakman MJ, Sturkenboom MC, Tiellac P, Tubaro A, Vallencien G, Vela Navarrete R (2002) Triumph Pan European Expert Panel. Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care—the Triumph project. Eur Urol 42(4):323–328CrossRefPubMed

AUA practice guidelines committee (2003) AUA guideline on management of benign prostatic hyperplasia. Chapter 1: diagnosis and treatment recommendations. J Urol 170:530–547CrossRef

Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC, N’Dow J, Nordling J, de la Rosette JJ, European Association of Urology (2013) EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 64(1):118–140CrossRefPubMed

Roehrborn CG, Siami P, Barkin J, Damião R, Major-Walker K, Nandy I, Morrill BB, Gagnier RP, Montorsi F, CombAT Study Group (2010) The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 57(1):123–131CrossRefPubMed

Erdemir F, Harbin A, Hellstrom WJ (2008) 5-Alpha reductase inhibitors and erectile dysfunction: the connection. J Sex Med 5(12):2917–2924CrossRefPubMed

Gur S, Kadowitz PJ, Hellstrom WJ (2013) Effects of 5-alpha reductase inhibitors on erectile function, sexual desire and ejaculation. Expert Opin Drug Saf 12(1):81–90CrossRefPubMed

Seftel A, Rosen R, Kuritzky L (2007) Physician perceptions of sexual dysfunction related to benign prostatic hyperplasia (BPH) symptoms and sexual side effects related to BPH medications. Int J Impot Res 19(4):386–392CrossRefPubMed

Burnett AL (2006) The role of nitric oxide in erectile dysfunction: implications for medical therapy. J Clin Hypertens 8:53–62CrossRef

Napalkov P, Maisonneuve P, Boyle P (1995) Worldwide patterns of prevalence and mortality from benign prostatic hyperplasia. Urology 46:41–46CrossRefPubMed

10.

McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, Lepor H, McVary KT, Nyberg LM Jr, Clarke HS, Crawford ED, Diokno A, Foley JP, Foster HE, Jacobs SC, Kaplan SA, Kreder KJ, Lieber MM, Lucia MS, Miller GJ, Menon M, Milam DF, Ramsdell JW, Schenkman NS, Slawin KM, Smith JA, Medical Therapy of Prostatic Symptoms (MTOPS) Research Group (2003) The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349(25):2387–2398CrossRefPubMed

11.

McVary KT (2006) BPH: epidemiology and comorbidities. Am J Manag Care 12(5 Suppl):S122–S128PubMed

12.

Sarma AV, Kellogg Parsons J (2009) Diabetes and benign prostatic hyperplasia: emerging clinical connections. Curr Urol Rep 10(4):267–275CrossRefPubMed

13.

Stamatiou K, Lardas M, Kostakos E, Koutsonasios V, Michail E (2009) The impact of diabetes type 2 in the pathogenesis of benign prostatic hyperplasia: a review. Adv Urol 1–3. doi:10.1155/2009/818965

14.

Lekili M, Müezzinoğlu T, Uyanik BS, Büyüksu C (2006) Serum lipid levels in benign prostatic hyperplasia. World J Urol 24(2):210–213CrossRefPubMed

15.

Andriole GL, Kirby R (2003) Safety and tolerability of the dual 5-alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia. Eur Urol 44:82–88CrossRefPubMed

Title: Demographic and comorbidity profile of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a real-life clinical setting: Are 5-alpha-reductase inhibitor consumers different?
Authors: Ferdinando Fusco
Davide Arcaniolo
Massimiliano Creta
Gaetano Piccinocchi
Giovanni Arpino
Matteo Laringe
Roberto Piccinocchi
Nicola Longo
Paolo Verze
Francesco Mangiapia
Vittorio Imperatore
Vincenzo Mirone
Publication date: 01-05-2015
Publisher: Springer Berlin Heidelberg
Published in: World Journal of Urology / Issue 5/2015
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-014-1460-9

At a glance: The STEP trials

Springer Medicine

Demographic and comorbidity profile of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a real-life clinical setting: Are 5-alpha-reductase inhibitor consumers different?

Abstract

Purpose

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2015

Prevalence, risk factors, and symptom bother of nocturia: a population-based survey in China

Matched-pair analysis of renal function in the immediate postoperative period: a comparison of living kidney donors versus patients nephrectomized for renal cell cancer

Circumcision plus antibiotic, anti-inflammatory, and α-blocker therapy for the treatment for chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, multicenter trial

Safety, efficacy and reliability of 180-W GreenLight laser technology for prostate vaporization: review of the literature

Add-on anticholinergic therapy for residual nocturia in patients with lower urinary tract symptoms receiving α1-blocker treatment: a multi-centre, prospective, randomised study

Comparison of treatment outcomes according to output voltage during shockwave lithotripsy for ureteral calculi: a prospective randomized multicenter study